Biologics - beyond the joints

Zoltán Szekanecz, Sándor Szántó, Zoltán Szabó, Andrea Váncsa, Szilvia Szamosi, Nóra Bodnár, Gabriella Szücs

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Biologics including tumor necrosis factor α (TNF-α), interleukin-6 receptor (IL-6R), T and B cell inhibitors are very effective therapeutic agents for the treatment of arthritides. These compounds effectively improve articular symptoms and inhibit joint damage. In this respect, there are no major differences in the efficacy of the available biologics. However, many arthritis patients also exert extra-articular features, systemic manifestations of the disease. These associated conditions include uveitis, inflammatory bowel disease, psoriasis, secondary bone loss and cardiovascular disease. There have been data suggesting that there may be differences in the effects of various TNF inhibitors, rituximab and tocilizumab on the systemic manifestations described above. At present, we do not always have sufficient evidence to confirm these differences, therefore, more information should be obtained from large trials and long-term observational studies.

Original languageEnglish
Pages (from-to)820-824
Number of pages5
JournalAutoimmunity Reviews
Volume9
Issue number12
DOIs
Publication statusPublished - Oct 1 2010

    Fingerprint

Keywords

  • Ankylosing spondylitis
  • Atherosclerosis
  • Biologics
  • Cardiovascular disease
  • Inflammatory bowel disease
  • Psoriasis
  • Rheumatoid arthritis
  • Uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this